Head-To-Head Contrast: HCW Biologics (NASDAQ:HCWB) & Insmed (NASDAQ:INSM)

HCW Biologics (NASDAQ:HCWB – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Volatility & Risk

HCW Biologics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares HCW Biologics and Insmed”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HCW Biologics $50,000.00 47.04 -$7.96 million ($27.57) -0.03
Insmed $606.42 million 51.13 -$1.28 billion ($2.82) -50.12

HCW Biologics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

3.0% of HCW Biologics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for HCW Biologics and Insmed, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HCW Biologics 1 0 1 0 2.00
Insmed 1 1 23 1 2.92

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 3,904.81%. Insmed has a consensus target price of $196.52, suggesting a potential upside of 39.05%. Given HCW Biologics’ higher possible upside, research analysts plainly believe HCW Biologics is more favorable than Insmed.

Profitability

This table compares HCW Biologics and Insmed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HCW Biologics -83.03% -194.06% -35.22%
Insmed -39.85% -96.38% -32.55%

Summary

Insmed beats HCW Biologics on 9 of the 15 factors compared between the two stocks.

About HCW Biologics

(Get Free Report)

HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies designed to address chronic inflammation, which the company views as a contributor to aging and age-related diseases. Its research also includes potential treatments for cancer and other serious conditions. The company uses proprietary biologics platforms to discover and develop engineered therapeutic candidates. Its pipeline includes investigational fusion-protein therapies intended to modulate immune activity; these candidates remain under clinical development and are not approved for commercial use.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.